178 related articles for article (PubMed ID: 22552627)
1. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Bou Zgheib N; Xiong Y; Marchion DC; Bicaku E; Chon HS; Stickles XB; Sawah EA; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Cubitt CL; Chen DT; Lancaster JM
Int J Oncol; 2012 Jul; 41(1):179-88. PubMed ID: 22552627
[TBL] [Abstract][Full Text] [Related]
2. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Marchion DC; Cottrill HM; Xiong Y; Chen N; Bicaku E; Fulp WJ; Bansal N; Chon HS; Stickles XB; Kamath SG; Hakam A; Li L; Su D; Moreno C; Judson PL; Berchuck A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Bloom GC; Eschrich SA; Sebti S; Chen DT; Lancaster JM
Clin Cancer Res; 2011 Oct; 17(19):6356-66. PubMed ID: 21849418
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
4. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
5. The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.
Al Sawah E; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Boac BM; Bush SH; Bou Zgheib N; McClung EC; Khulpateea BR; Berry A; Hakam A; Wenham RM; Lancaster JM; Judson PL
J Cancer Res Clin Oncol; 2015 Feb; 141(2):237-42. PubMed ID: 25164128
[TBL] [Abstract][Full Text] [Related]
6. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.
Marchion DC; Xiong Y; Chon HS; Al Sawah E; Bou Zgheib N; Ramirez IJ; Abbasi F; Stickles XB; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund AE; Lancaster JM
Am J Obstet Gynecol; 2013 Dec; 209(6):576.e1-576.e16. PubMed ID: 23933223
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
[TBL] [Abstract][Full Text] [Related]
8. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
[TBL] [Abstract][Full Text] [Related]
9. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
[TBL] [Abstract][Full Text] [Related]
10. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.
Bicaku E; Xiong Y; Marchion DC; Chon HS; Stickles XB; Chen N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Fulp W; Cubitt CL; Chen DT; Lancaster JM
Br J Cancer; 2012 Jun; 106(12):1967-75. PubMed ID: 22596241
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
Hernández-Vargas H; Rodríguez-Pinilla SM; Julián-Tendero M; Sánchez-Rovira P; Cuevas C; Antón A; Ríos MJ; Palacios J; Moreno-Bueno G
Breast Cancer Res Treat; 2007 Apr; 102(2):157-72. PubMed ID: 17039268
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.
Bush SH; Tollin S; Marchion DC; Xiong Y; Abbasi F; Ramirez IJ; Zgheib NB; Boac B; Judson PL; Chon HS; Wenham RM; Apte SM; Cubitt CL; Berglund AE; Havrilesky LJ; Lancaster JM
Mol Clin Oncol; 2016 Mar; 4(3):399-404. PubMed ID: 26998291
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
14. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
15. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
17. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
Yang C; Xu M; Shen HJ; Zhu HY; Li F; He M; Chen T; Wang J; Shi WJ; Ji F
Int J Clin Exp Pathol; 2014; 7(2):521-8. PubMed ID: 24551272
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
20. Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis.
Nakai Y; Otsuka M; Hoshida Y; Tada M; Komatsu Y; Kawabe T; Omata M
Oncol Rep; 2005 Nov; 14(5):1263-7. PubMed ID: 16211294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
